26.01 USD
+0.65 (+2.56%)
26.01 USD
0 (0%)
Overall AMPH gets a fundamental rating of 6 out of 10. We evaluated AMPH against 192 industry peers in the Pharmaceuticals industry. AMPH scores excellent on profitability, but there are some minor concerns on its financial health. AMPH may be a bit undervalued, certainly considering the very reasonable score on growth These ratings would make AMPH suitable for value investing!
1. Profitability
1.1 Basic Checks
AMPH had positive earnings in the past year.
In the past year AMPH had a positive cash flow from operations.
Each year in the past 5 years AMPH has been profitable.
AMPH had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
The Return On Assets of AMPH (8.34%) is better than 90.10% of its industry peers.
AMPH has a better Return On Equity (17.78%) than 90.10% of its industry peers.
The Return On Invested Capital of AMPH (10.47%) is better than 89.58% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for AMPH is in line with the industry average of 13.48%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 8.34% | ||
| ROE | 17.78% | ||
| ROIC | 10.47% |
ROA(3y)10.51%
ROA(5y)8.2%
ROE(3y)20.19%
ROE(5y)14.97%
ROIC(3y)12.92%
ROIC(5y)10.14%
1.3 Margins
AMPH's Profit Margin of 18.64% is amongst the best of the industry. AMPH outperforms 90.63% of its industry peers.
In the last couple of years the Profit Margin of AMPH has grown nicely.
AMPH has a better Operating Margin (25.14%) than 91.67% of its industry peers.
AMPH's Operating Margin has improved in the last couple of years.
AMPH has a better Gross Margin (49.86%) than 63.02% of its industry peers.
In the last couple of years the Gross Margin of AMPH has grown nicely.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 25.14% | ||
| PM (TTM) | 18.64% | ||
| GM | 49.86% |
OM growth 3Y20.68%
OM growth 5YN/A
PM growth 3Y15.39%
PM growth 5Y7.52%
GM growth 3Y3.84%
GM growth 5Y4.54%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), AMPH is creating some value.
AMPH has less shares outstanding than it did 1 year ago.
Compared to 5 years ago, AMPH has more shares outstanding
The debt/assets ratio for AMPH has been reduced compared to a year ago.
2.2 Solvency
AMPH has an Altman-Z score of 2.49. This is not the best score and indicates that AMPH is in the grey zone with still only limited risk for bankruptcy at the moment.
AMPH has a Altman-Z score of 2.49. This is in the better half of the industry: AMPH outperforms 66.67% of its industry peers.
The Debt to FCF ratio of AMPH is 5.54, which is a neutral value as it means it would take AMPH, 5.54 years of fcf income to pay off all of its debts.
With an excellent Debt to FCF ratio value of 5.54, AMPH belongs to the best of the industry, outperforming 80.73% of the companies in the same industry.
A Debt/Equity ratio of 0.80 indicates that AMPH is somewhat dependend on debt financing.
With a Debt to Equity ratio value of 0.80, AMPH is not doing good in the industry: 69.79% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.8 | ||
| Debt/FCF | 5.54 | ||
| Altman-Z | 2.49 |
ROIC/WACC1.25
WACC8.37%
2.3 Liquidity
A Current Ratio of 3.29 indicates that AMPH has no problem at all paying its short term obligations.
AMPH's Current ratio of 3.29 is in line compared to the rest of the industry. AMPH outperforms 54.17% of its industry peers.
AMPH has a Quick Ratio of 2.21. This indicates that AMPH is financially healthy and has no problem in meeting its short term obligations.
With a Quick ratio value of 2.21, AMPH perfoms like the industry average, outperforming 45.31% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.29 | ||
| Quick Ratio | 2.21 |
3. Growth
3.1 Past
AMPH shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -9.95%.
The Earnings Per Share has been growing by 61.62% on average over the past years. This is a very strong growth
Looking at the last year, AMPH shows a quite strong growth in Revenue. The Revenue has grown by 13.59% in the last year.
AMPH shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 17.82% yearly.
EPS 1Y (TTM)-9.95%
EPS 3Y41.58%
EPS 5Y61.62%
EPS Q2Q%-3.12%
Revenue 1Y (TTM)13.59%
Revenue growth 3Y18.69%
Revenue growth 5Y17.82%
Sales Q2Q%0.33%
3.2 Future
Based on estimates for the next years, AMPH will show a small growth in Earnings Per Share. The EPS will grow by 0.50% on average per year.
The Revenue is expected to grow by 4.23% on average over the next years.
EPS Next Y-11.92%
EPS Next 2Y-1.77%
EPS Next 3Y1.01%
EPS Next 5Y0.5%
Revenue Next Year-1.41%
Revenue Next 2Y2.05%
Revenue Next 3Y2.4%
Revenue Next 5Y4.23%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
AMPH is valuated cheaply with a Price/Earnings ratio of 7.56.
Based on the Price/Earnings ratio, AMPH is valued cheaper than 93.23% of the companies in the same industry.
The average S&P500 Price/Earnings ratio is at 25.45. AMPH is valued rather cheaply when compared to this.
Based on the Price/Forward Earnings ratio of 6.98, the valuation of AMPH can be described as very cheap.
AMPH's Price/Forward Earnings ratio is rather cheap when compared to the industry. AMPH is cheaper than 93.75% of the companies in the same industry.
AMPH is valuated cheaply when we compare the Price/Forward Earnings ratio to 34.46, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 7.56 | ||
| Fwd PE | 6.98 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, AMPH is valued cheaply inside the industry as 93.75% of the companies are valued more expensively.
Based on the Price/Free Cash Flow ratio, AMPH is valued cheaper than 89.06% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 11 | ||
| EV/EBITDA | 6.44 |
4.3 Compensation for Growth
The excellent profitability rating of AMPH may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)0.12
EPS Next 2Y-1.77%
EPS Next 3Y1.01%
5. Dividend
5.1 Amount
AMPH does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
26.01
+0.65 (+2.56%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners71.91%
Inst Owner Change0.4%
Ins Owners9.28%
Ins Owner Change6.19%
Market Cap1.21B
Revenue(TTM)731.97M
Net Income(TTM)134.71M
Analysts78.33
Price Target33.05 (27.07%)
Short Float %11.87%
Short Ratio9.45
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)9.06%
Min EPS beat(2)5.65%
Max EPS beat(2)12.46%
EPS beat(4)2
Avg EPS beat(4)2.21%
Min EPS beat(4)-4.74%
Max EPS beat(4)12.46%
EPS beat(8)5
Avg EPS beat(8)11.25%
EPS beat(12)8
Avg EPS beat(12)16.86%
EPS beat(16)12
Avg EPS beat(16)21.21%
Revenue beat(2)0
Avg Revenue beat(2)-1.89%
Min Revenue beat(2)-2.43%
Max Revenue beat(2)-1.36%
Revenue beat(4)0
Avg Revenue beat(4)-2.59%
Min Revenue beat(4)-3.71%
Max Revenue beat(4)-1.36%
Revenue beat(8)2
Avg Revenue beat(8)-1.01%
Revenue beat(12)5
Avg Revenue beat(12)-0.37%
Revenue beat(16)9
Avg Revenue beat(16)0.92%
PT rev (1m)-0.6%
PT rev (3m)0.76%
EPS NQ rev (1m)-3.19%
EPS NQ rev (3m)-5.47%
EPS NY rev (1m)-0.99%
EPS NY rev (3m)6.02%
Revenue NQ rev (1m)-0.76%
Revenue NQ rev (3m)-0.94%
Revenue NY rev (1m)-0.62%
Revenue NY rev (3m)-0.18%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 7.56 | ||
| Fwd PE | 6.98 | ||
| P/S | 1.67 | ||
| P/FCF | 11 | ||
| P/OCF | 7.58 | ||
| P/B | 1.6 | ||
| P/tB | 6.76 | ||
| EV/EBITDA | 6.44 |
EPS(TTM)3.44
EY13.23%
EPS(NY)3.72
Fwd EY14.32%
FCF(TTM)2.36
FCFY9.09%
OCF(TTM)3.43
OCFY13.2%
SpS15.54
BVpS16.29
TBVpS3.85
PEG (NY)N/A
PEG (5Y)0.12
Graham Number35.51
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 8.34% | ||
| ROE | 17.78% | ||
| ROCE | 12.63% | ||
| ROIC | 10.47% | ||
| ROICexc | 12.47% | ||
| ROICexgc | 23.95% | ||
| OM | 25.14% | ||
| PM (TTM) | 18.64% | ||
| GM | 49.86% | ||
| FCFM | 15.21% |
ROA(3y)10.51%
ROA(5y)8.2%
ROE(3y)20.19%
ROE(5y)14.97%
ROIC(3y)12.92%
ROIC(5y)10.14%
ROICexc(3y)16.46%
ROICexc(5y)13%
ROICexgc(3y)29.66%
ROICexgc(5y)21.24%
ROCE(3y)15.59%
ROCE(5y)12.24%
ROICexgc growth 3Y24.9%
ROICexgc growth 5YN/A
ROICexc growth 3Y2.33%
ROICexc growth 5YN/A
OM growth 3Y20.68%
OM growth 5YN/A
PM growth 3Y15.39%
PM growth 5Y7.52%
GM growth 3Y3.84%
GM growth 5Y4.54%
F-Score5
Asset Turnover0.45
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.8 | ||
| Debt/FCF | 5.54 | ||
| Debt/EBITDA | 2.59 | ||
| Cap/Depr | 93.66% | ||
| Cap/Sales | 6.88% | ||
| Interest Coverage | 7.38 | ||
| Cash Conversion | 68.01% | ||
| Profit Quality | 81.61% | ||
| Current Ratio | 3.29 | ||
| Quick Ratio | 2.21 | ||
| Altman-Z | 2.49 |
F-Score5
WACC8.37%
ROIC/WACC1.25
Cap/Depr(3y)91.01%
Cap/Depr(5y)109.44%
Cap/Sales(3y)5.45%
Cap/Sales(5y)6.46%
Profit Quality(3y)95%
Profit Quality(5y)414.14%
High Growth Momentum
Growth
EPS 1Y (TTM)-9.95%
EPS 3Y41.58%
EPS 5Y61.62%
EPS Q2Q%-3.12%
EPS Next Y-11.92%
EPS Next 2Y-1.77%
EPS Next 3Y1.01%
EPS Next 5Y0.5%
Revenue 1Y (TTM)13.59%
Revenue growth 3Y18.69%
Revenue growth 5Y17.82%
Sales Q2Q%0.33%
Revenue Next Year-1.41%
Revenue Next 2Y2.05%
Revenue Next 3Y2.4%
Revenue Next 5Y4.23%
EBIT growth 1Y-20.98%
EBIT growth 3Y43.24%
EBIT growth 5YN/A
EBIT Next Year-1.68%
EBIT Next 3Y1.08%
EBIT Next 5Y5.95%
FCF growth 1Y9.39%
FCF growth 3Y34.69%
FCF growth 5Y286.43%
OCF growth 1Y21.97%
OCF growth 3Y29.62%
OCF growth 5Y38.57%
AMPHASTAR PHARMACEUTICALS IN / AMPH FAQ
What is the fundamental rating for AMPH stock?
ChartMill assigns a fundamental rating of 6 / 10 to AMPH.
Can you provide the valuation status for AMPHASTAR PHARMACEUTICALS IN?
ChartMill assigns a valuation rating of 8 / 10 to AMPHASTAR PHARMACEUTICALS IN (AMPH). This can be considered as Undervalued.
Can you provide the profitability details for AMPHASTAR PHARMACEUTICALS IN?
AMPHASTAR PHARMACEUTICALS IN (AMPH) has a profitability rating of 8 / 10.
How financially healthy is AMPHASTAR PHARMACEUTICALS IN?
The financial health rating of AMPHASTAR PHARMACEUTICALS IN (AMPH) is 6 / 10.
What is the expected EPS growth for AMPHASTAR PHARMACEUTICALS IN (AMPH) stock?
The Earnings per Share (EPS) of AMPHASTAR PHARMACEUTICALS IN (AMPH) is expected to decline by -11.92% in the next year.